enGene Therapeutics Inc. last reported quarterly results on Sep 8, 2026, for Q3 FY2026 (the quarter ended Jul 31, 2026): diluted EPS of -$0.47. It usually reports 37–52 days after a quarter ends. Based on that pattern, the next release is estimated for around Dec 21, 2026.
Results for Q4 FY2026, the quarter ending around Oct 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Dec 22, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–52 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Sep 8, 2026
39 days after quarter end
|
Q3 FY2026
ended Jul 31, 2026
|
—
|
-33
-12.1%
|
-0.47
+17.5%
|
|
Jun 15, 2026
46 days after quarter end
|
Q2 FY2026
ended Apr 30, 2026
|
—
|
-30
-17.1%
|
-0.43
+15.7%
|
|
Mar 9, 2026
37 days after quarter end
|
Q1 FY2026
ended Jan 31, 2026
|
—
|
-30
-20.9%
|
0.44
-8.3%
|
|
Dec 22, 2025
52 days after quarter end
|
Q4 FY2025
ended Oct 31, 2025
|
—
|
-38
-147.6%
|
-0.74
-113.8%
|
|
Sep 11, 2025
42 days after quarter end
|
Q3 FY2025
ended Jul 31, 2025
|
—
|
-29
-104.9%
|
-0.57
-278.1%
|
|
Jun 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Apr 30, 2025
|
—
|
-26
-72.3%
|
-0.51
-234.2%
|
|
Mar 10, 2025
38 days after quarter end
|
Q1 FY2025
ended Jan 31, 2025
|
—
|
-25
-129.8%
|
0.48
+4.3%
|
|
Dec 19, 2024
49 days after quarter end
|
Q4 FY2024
ended Oct 31, 2024
|
—
|
-15
|
-0.34
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENGN (Nasdaq), ENGNW (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Saint-Laurent
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1980845
- Former names
- enGene Holdings Inc. (until Mar 9, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.